Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:NEOS
- CUSIP: N/A
- Web: www.neostx.com
Capitalization:- Market Cap: $184.68 million
- Outstanding Shares: 22,560,000
Average Prices:- 50 Day Moving Avg: $7.57
- 200 Day Moving Avg: $6.90
- 52 Week Range: $4.85 - $9.60
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.96
- P/E Growth: -0.02
Sales & Book Value:- Annual Revenue: $12.2 million
- Price / Sales: 12.20
- Book Value: $0.56 per share
- Price / Book: 11.79
Profitability:- EBIDTA: ($77,120,000.00)
- Net Margins: -719.86%
- Return on Equity: -512.10%
- Return on Assets: -87.88%
Debt:- Debt-to-Equity Ratio: 4.68%
- Current Ratio: 2.87%
- Quick Ratio: 2.66%
Misc:- Average Volume: 573,665 shs.
- Beta: -0.79
- Short Ratio: 8.37
Frequently Asked Questions for Neos Therapeutics (NASDAQ:NEOS)
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
How were Neos Therapeutics' earnings last quarter?
Neos Therapeutics, Inc. (NASDAQ:NEOS) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.07. The company earned $5.63 million during the quarter. Neos Therapeutics had a negative return on equity of 512.10% and a negative net margin of 719.86%. View Neos Therapeutics' Earnings History.
Where is Neos Therapeutics' stock going? Where will Neos Therapeutics' stock price be in 2017?
2 analysts have issued 1-year price targets for Neos Therapeutics' shares. Their predictions range from $15.00 to $20.00. On average, they anticipate Neos Therapeutics' share price to reach $17.50 in the next year. View Analyst Ratings for Neos Therapeutics.
Who are some of Neos Therapeutics' key competitors?
Some companies that are related to Neos Therapeutics include Collegium Pharmaceutical (COLL), Aquinox Pharmaceuticals (AQXP), Corium International (CORI), Tetraphase Pharmaceuticals (TTPH), Allergy Therapeutics plc (AGY), BioDelivery Sciences International (BDSI), Adamis Pharmaceuticals Corporation (ADMP), Aralez Pharmaceuticals (ARLZ), Intellipharmaceutics International (IPCI), Concordia International Corp. (CXRX), Diurnal Group PLC (DNL), Innocoll Holdings (INNL), Neuralstem (CUR), Juniper Pharmaceuticals (JNP), SCYNEXIS (SCYX), Amryt Pharma PLC (AMYT), Pernix Therapeutics Holdings (PTX) and Histogenics Corporation (HSGX).
Who are Neos Therapeutics' key executives?
Neos Therapeutics' management team includes the folowing people:
- Alan Heller, Chairman of the Board
- Vipin K. Garg Ph.D., President, Chief Executive Officer, Director
- Richard Eisenstadt, Chief Financial Officer
- Juergen A. Martens Ph.D., Chief Technology and Operations Officer
- Dorothy Engelking, Vice President of Regulatory Affairs
- Thomas P McDonnell, Chief Commercial Officer
- Beth P. Hecht, Director
- Paul R. Edick, Non-Executive Director
- Bryant E. Fong, Non-Executive Director
- Gregory J. Robitaille, Non-Executive Director
When did Neos Therapeutics IPO?
(NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.
How do I buy Neos Therapeutics stock?
Shares of Neos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neos Therapeutics' stock price today?
One share of Neos Therapeutics stock can currently be purchased for approximately $6.60.
MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Neos Therapeutics (NASDAQ:NEOS)Earnings History by Quarter for Neos Therapeutics (NASDAQ NEOS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | ($0.94) | ($0.87) | | $5.63 million | View | Listen |  |
| 3/14/2017 | Q4 2016 | ($1.36) | ($1.14) | | $3.50 million | View | N/A | |
| 11/10/2016 | Q3 2016 | ($1.64) | ($1.61) | | $1.58 million | View | N/A | |
| 8/11/2016 | Q2 | ($1.16) | ($1.65) | $1.48 million | $1.49 million | View | Listen | |
| 5/16/2016 | Q1 | ($0.87) | ($0.79) | $1.50 million | $2.58 million | View | Listen | |
| 3/17/2016 | Q4 | ($0.66) | ($0.57) | | $1.70 million | View | Listen | |
| 9/3/2015 | Q215 | ($4.31) | ($7.76) | $1.70 million | $1.48 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Neos Therapeutics (NASDAQ:NEOS)Current Year EPS Consensus Estimate: $-3.17 EPS
Next Year EPS Consensus Estimate: $-1.33 EPS
Dividend History for Neos Therapeutics (NASDAQ:NEOS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Neos Therapeutics (NASDAQ:NEOS)Insider Ownership Percentage: 5.17%
Institutional Ownership Percentage: 33.08%
Insider Trades by Quarter for Neos Therapeutics (NASDAQ:NEOS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/31/2016 | Bryant Fong | Director | Buy | 1,500 | $6.54 | $9,810.00 | |
| 8/25/2016 | Richard I Eisenstadt | CFO | Buy | 3,710 | $6.82 | $25,302.20 | |
| 6/13/2016 | Juergen Martens | Insider | Buy | 10,000 | $9.90 | $99,000.00 | |
| 5/19/2016 | Alan L Heller | Director | Buy | 10,000 | $7.61 | $76,100.00 | |
| 5/19/2016 | Thomas P Mcdonnell | Insider | Buy | 3,000 | $7.56 | $22,680.00 | |
| 5/18/2016 | Gregory J Robitaille | Director | Buy | 7,442 | $7.55 | $56,187.10 | |
| 4/20/2016 | Presidio Partners 2007, L.P. | Major Shareholder | Sell | 20,367 | $9.98 | $203,262.66 | |
| 4/15/2016 | Presidio Partners 2007, L.P. | Major Shareholder | Sell | 57,968 | $10.23 | $593,012.64 | |
(Data available from 1/1/2013 forward)
Headline Trends for Neos Therapeutics (NASDAQ:NEOS)
Latest Headlines for Neos Therapeutics (NASDAQ:NEOS)
| Source: |
|
| Date | Headline |
|---|
 | Neos Therapeutics, Inc. (NASDAQ:NEOS) Expected to Post Earnings of -$0.83 Per Share
www.americanbankingnews.com - July 20 at 12:24 AM |
 | Neos Looks Attractive With Short And Long Term Catalysts
seekingalpha.com - July 1 at 3:36 AM |
 | Attention To Details: Neos' ADHD Portfolio
www.benzinga.com - June 27 at 6:53 PM |
 | BRIEF-Neos Therapeutics announces proposed offering of common stock
www.reuters.com - June 27 at 6:53 PM |
 | Form 8-K Neos Therapeutics, Inc. For: Jun 26
www.streetinsider.com - June 27 at 6:53 PM |
 | Neos Therapeutics Announces Pricing of Underwritten Public Offering of $32.4 Million of Common Stock
finance.yahoo.com - June 27 at 6:53 PM |
| Neos Therapeutics, Inc. (NEOS) Expected to Post Earnings of -$0.83 Per Share
www.americanbankingnews.com - June 23 at 10:24 PM |
 | Neos nets second ADHD drug approval - for no-swallow, dissolve pill
www.bizjournals.com - June 23 at 7:19 PM |
| Shire wins U.S. approval for long-acting ADHD drug
finance.yahoo.com - June 21 at 5:56 AM |
| Neos Therapeutics, Inc. (NEOS) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - June 20 at 11:40 PM |
 | Neos Therapeutics Slides Despite FDA Approval
247wallst.com - June 20 at 7:53 PM |
| Shire's long-acting ADHD drug wins U.S. approval
finance.yahoo.com - June 20 at 7:53 PM |
| Neos Therapeutics, Inc. (NEOS) Receives Outperform Rating from BMO Capital Markets
www.americanbankingnews.com - June 20 at 12:28 PM |
 | Neos Therapeutics Says ADHD Drug Cotempla XR-ODT Gets FDA Approval
www.nasdaq.com - June 20 at 7:45 AM |
| Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
finance.yahoo.com - June 19 at 10:53 PM |
| Neos Therapeutics to Present at the JMP Securities 2017 Life Sciences Conference
finance.yahoo.com - June 14 at 9:25 AM |
| Neos Therapeutics, Inc. (NEOS) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - June 13 at 4:40 PM |
| Neos Therapeutics Inc (NEOS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 10 at 7:26 AM |
| BRIEF-Neos Therapeutics enters into first amendment to its existing facility agreement with lenders
www.reuters.com - June 5 at 7:27 PM |
| Zacks Investment Research Upgrades Neos Therapeutics Inc (NEOS) to Buy
www.americanbankingnews.com - June 3 at 7:12 AM |
| Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study
www.reuters.com - May 31 at 9:46 AM |
| Brokerages Anticipate Neos Therapeutics Inc (NEOS) to Post -$0.83 Earnings Per Share
www.americanbankingnews.com - May 30 at 4:24 PM |
| Neos Therapeutics to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 30 at 7:31 AM |
| Two Red Hot Biotechs With Big Near-term Catalysts Ahead
finance.yahoo.com - May 28 at 7:13 PM |
| Neos Therapeutics Inc (NEOS) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - May 27 at 3:14 PM |
| Neos Therapeutics Inc (NEOS) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 27 at 7:46 AM |
| Neos Therapeutics Inc (NEOS) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 18 at 11:34 PM |
| Neos Therapeutics Inc (NEOS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 18 at 3:28 PM |
| Neos Therapeutics to Present at 2017 UBS Global Healthcare Conference
finance.yahoo.com - May 16 at 10:15 AM |
| Neos Therapeutics Inc (NEOS) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - May 10 at 4:56 PM |
 | Neos Therapeutics Reports First Quarter 2017 Financial Results
globenewswire.com - May 9 at 11:34 AM |
 | Neos Therapeutics reports 1Q loss
marketbeat.com - May 9 at 9:41 AM |
| Zacks: Analysts Expect Neos Therapeutics Inc (NEOS) Will Post Earnings of -$0.89 Per Share
www.americanbankingnews.com - May 4 at 10:50 PM |
| Neos Therapeutics (NEOS) Earns Daily Coverage Optimism Rating of 0.24
www.americanbankingnews.com - May 3 at 11:18 PM |
| Neos Therapeutics to Host First Quarter 2017 Financial Results Conference Call on May 9, 2017
finance.yahoo.com - May 2 at 2:37 PM |
| Neos Therapeutics Inc (NEOS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 9:32 AM |
| Neos Therapeutics (NEOS) Earns Daily Media Impact Score of -0.04
www.americanbankingnews.com - April 27 at 6:24 PM |
| Neos Therapeutics (NEOS) Receives Daily Media Sentiment Score of 0.17
www.americanbankingnews.com - April 24 at 8:48 PM |
| Neos Therapeutics (NEOS) Receives News Sentiment Score of 0.28
www.americanbankingnews.com - April 22 at 12:17 AM |
| Short Interest in Neos Therapeutics Inc (NEOS) Rises By 7.5%
www.americanbankingnews.com - April 20 at 5:56 PM |
| Neos Therapeutics (NEOS) Receives Media Impact Score of -0.12
www.americanbankingnews.com - April 17 at 3:58 PM |
| Neos Therapeutics (NEOS) Given Daily Media Sentiment Rating of 0.03
www.americanbankingnews.com - April 14 at 2:52 PM |
| Zacks: Brokerages Expect Neos Therapeutics Inc (NEOS) Will Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - April 13 at 8:30 PM |
 | Bloomberg Markets: Dave Wilson’s Stock of the Day for April 5
www.bloomberg.com - April 7 at 11:26 AM |
| Neos Therapeutics Inc (NEOS) Receives New Coverage from Analysts at Cowen and Company
www.americanbankingnews.com - April 6 at 12:25 AM |
| Neos Therapeutics Inc (NEOS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 5 at 2:39 PM |
| Neos Therapeutics downgraded by UBS
finance.yahoo.com - March 20 at 4:55 PM |
| Neos Therapeutics Inc (NEOS) Lowered to “Hold” at Zacks Investment Research
www.americanbankingnews.com - March 18 at 8:46 AM |
| NEOS THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 15 at 6:58 PM |
| Neos Therapeutics Inc (NEOS) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 15 at 10:10 AM |
Neos Therapeutics (NEOS) Chart for Saturday, July, 22, 2017
